Introduction {#sec0005}
============

Epilepsy is one of the most common neurological disorders in the world, affecting about 69 million people worldwide, with 90 percent living in low- and middle-income countries (LMICs) ([@bib0140]). It contributes nearly one percent to the global burden of disease ([@bib0120]), and 20 percent of the global burden of epilepsy is in Africa ([@bib0220]).

While these figures suggest a large burden of epilepsy in Africa, they are derived from a limited number of studies that employ different case definitions and methodologies. Studies suggest that utilizing hospital records in LMICs to detect epilepsy under-estimates the prevalence by at least 80 percent due to limited health care utilization by people with epilepsy (PWE) in these settings ([@bib0160]). Thus, population-based surveys are frequently used to estimate prevalence, though not without limitations, including the absence of well-demarcated populations and vital statistics registries. This limitation, coupled with the lack of trained medical personnel available to make the diagnosis of epilepsy, makes estimating the burden of epilepsy in sub-Saharan Africa unusually challenging.

A recent systematic review and meta-analysis highlighted the significant variation in the prevalence of epilepsy between high-income countries and LMICs, with a higher prevalence in LMICs, especially in rural settings ([@bib0140]). The authors suggest that study size and the economic development level of the study country largely explain the heterogeneity, although increases in obstetric injury, head injuries, and infections and infestations of the central nervous system (CNS) ([@bib0130]), such as toxoplasmosis and toxocara ([@bib0205]), malaria ([@bib0025]) and human immunodeficiency virus (HIV) are thought to contribute ([@bib0140]), but there is little data from South Africa where the prevalence of HIV is very high.

As part of a multi-centre study on the epidemiology of epilepsy in demographic sites (SEEDS) ([@bib0145]), we conducted a three-stage, population-based survey and a case-control study to determine the prevalence of and risk factors for active convulsive epilepsy (ACE) in rural South Africa. In particular, we were interested in examining the risk factors for ACE in a non-malaria endemic area, particularly HIV since it has a high prevalence in South Africa.

Methodology {#sec0010}
===========

Population and study area {#sec0015}
-------------------------

The study was conducted in the rural Agincourt health sub-district, in which the Agincourt health and socio-demographic surveillance system (HDSS) operates and is located 500 kilometers northeast of Johannesburg ([Fig. 1](#fig0005){ref-type="fig"}). The Agincourt HDSS was established in 1992 as a research platform to inform health and development policy through evidence-based research ([@bib0085]). The population has been enumerated through an annual census update, following baseline measurement in 1992 and captures vital statistics including births, deaths, and in- and out-migrations.

In 2008, the population was 83,121 individuals in 15,841 households and 25 villages on 420 km^2^ of semi-arid scrubland. The site forms part of a former *bantustan*, or ethnic 'homeland' implemented during the Apartheid era. The population is mainly Xi-Tsonga speaking, with one-third (32.8%) originally from Mozambique.

The leading causes of death ascertained through the Agincourt HDSS are HIV/AIDS, cardiovascular disease and trauma (road traffic accidents, assaults) ([@bib0195]). Six government clinics, one larger government health centre, and one public-private community health centre, with its main focus being HIV and tuberculosis, provide primary health care services for the population. Referrals are to three government district hospitals located 25 to 55 km from the sub-district.

Ethics {#sec0020}
------

Ethical clearance for the study was received from the Human Research Ethics Committee of the University of the Witwatersrand, Johannesburg, South Africa (Clearance number: M080455) and the Mpumalanga Province Department of Health\'s Research and Ethics committee. Written informed consent was sought from each participant in the study. Parental or guardian informed consent was sought in the case of children or patients with cognitive impairment, with verbal assent being sought from children and cognitively impaired patients.

Case definition of active convulsive epilepsy (ACE) {#sec0025}
---------------------------------------------------

We identified patients with Active convulsive epilepsy (ACE) since convulsive epilepsies are associated with increased morbidity, mortality ([@bib0045]) and greater social stigma than non-convulsive epilepsies ([@bib0215]). ACE was defined as having two or more unprovoked convulsive seizures occurring more than 24 hours apart, with at least one seizure occurring in the 12 months preceding the study or currently taking anti-epileptic drugs (AEDs) ([@bib0050]).

Procedures {#sec0030}
----------

Between August and November 2008, two questions ('Do you have fits or has someone ever told you that you have fits?' and 'Do you experience episodes in which you legs or arms have jerking movements or fall to the ground and lose consciousness?'), used previously in a similar study ([@bib0050]), were administered by census fieldworkers to a senior member of each household (*n* = 15,841) on behalf of each member of the household. The questions had been piloted previously in the local language (Xi-Tsonga) at a district hospital and had a high specificity (100%) and sensitivity (98%). The questions were included in the 2008 annual Agincourt HDSS census update round. The two questions within the census update constituted Stage I of the study and sought to identify all people who had experienced a seizure prior to 1 August 2008 (the prevalence day).

In Stage II (August--December 2008), trained fieldworkers visited all individuals who responded 'yes' to either of the two questions in Stage I and asked a detailed questionnaire, based on previous studies ([@bib0165]), about the characteristics and history of the seizures. Fieldworkers were specifically trained by the study managers (RGW, AKN) and study neurologist (CRN) on the administration of this questionnaire. Individuals who had experienced at least two seizures in their lifetime and at least one seizure with abnormal movement (aimed at identifying convulsive epilepsy) in the preceding 12 months or currently taking AEDs were invited for further assessment in the epilepsy clinic within the following week (Stage III).

In Stage III (September 2008--February 2009), socio-demographic information was obtained and a specially trained nurse made the diagnosis of ACE, based on a positive clinical history provided by the patient\'s caregiver or family member. A clinical examination was completed to identify neurological abnormalities and physical co-morbidities. Blood was drawn from each patient for serological testing. A neurologist (CRN) confirmed the diagnosis of epilepsy by reviewing all of the patient records and examining selected patients.

Population sample {#sec0035}
-----------------

In addition to identifying cases of epilepsy through the population screen (Stage I), a random sample of 4,500 individuals (all ages and both sexes), from the Agincourt HDSS, were screened with the Stage II tool. This population sample simulated the traditional two-stage epilepsy prevalence study design ([@bib0165]) and was used to evaluate the three-stage methodology of this study. Those who screened positive were referred for assessment in Stage III and included as cases in the case-control study.

Furthermore, individuals who were referred to the epilepsy clinic by sources (clinic staff and community leaders) other than the three-stage study were clinically assessed and those found to have ACE were included as cases in the case-control study.

Selection of controls for case control study {#sec0040}
--------------------------------------------

Controls were selected randomly from those that screened negative for epilepsy in the population sample and frequency matched to cases diagnosed with ACE during Stage III of the study (on age-bands 0--5, 6--12, 13--18, 19--28, 29--49, and 50+ years). If the selected control was not found after three attempted visits, another control was selected randomly as a replacement. For each control selected, a clinical history and blood sample were taken and a clinical examination performed.

Serological testing {#sec0045}
-------------------

Blood from cases and controls was collected in Stage III of the study and exposure to *Toxocara canis* excretory-secretory antigen with a sensitivity of 97.1% and specificity of 78.6% ([@bib0150]), toxoplasmosis (Toxoplasma IgG ELISA Kit, Genesis Diagnostics Ltd, Product Code GD80 ([@bib0090])), and *Plasmodium falciparum* IgG antibodies tested by ELISA was examined. Exposure to the larval stage (cysticercosis) and adult stage (taeniasis) of the parasite *T. solium* in the patients only, given the absence of cysticersosis reported by the local radiologists. HIV antibodies (Vironostika HIV Uni-form II Ag/Ab Kit) were also measured after written informed consent was received from each individual or their legal guardian.

Statistical analysis {#sec0050}
--------------------

Data were double entered into a mySQL database (OracleCorp, Redwood Shores, CA, USA). All analyses were conducted using Stata 10 (StataCorp, College Station, TX, USA).

We adjusted for attrition between the stages of the survey using a multiple imputation method. The figures were also adjusted for the sensitivity of the three-stage method, previously calculated in a separate study ([@bib0135]) ([Table 1](#tbl0005){ref-type="table"}). We report adjusted prevalence by age, sex, and village of residence. We also present prevalence estimates standardized to the 2000 US population ([@bib0200]) to allow for global comparison and the median and interquartile range of age of onset of ACE. Finally, we report the adjusted prevalence figures from the population sample of 4,500 individuals.

Factors associated with active convulsive epilepsy {#sec0055}
--------------------------------------------------

In the case-control study, we performed analysis on 20 socio-demographic and clinical variables and four serological variables ([Table 3](#tbl0015){ref-type="table"}). We developed models using logistic regression and in each model included a variable of interest, adjusted for age and sex. In patients \>18 years of age, variables on whether alcohol was consumed and period of consumption were analyzed. Three additional variables were analyzed for patients \<18 years old: mother\'s marital status, whether the mother experienced some formal education, and her level of education.

Results {#sec0060}
=======

Participation in the three-stages of the survey is displayed in [Fig. 2](#fig0010){ref-type="fig"}.

Prevalence {#sec0065}
----------

We identified 245 cases of ACE in the three-stage study. The unadjusted prevalence of ACE was 3.0/1,000 individuals (95%CI: 2.6--3.3) within the three-stage study. Adjusting for attrition and the sensitivity of the three-stage methodology (48.6%), the adjusted crude prevalence was 7.0/1,000 (95%CI: 6.4--7.6). The sensitivity of 48.6% for the three-stage methodology was derived from a validation study performed in Kenya using clinical assessments as the gold standard ([@bib0135]). The prevalence, standardized to the age distribution of the US population in 2000 and adjusted for attrition and sensitivity of the three-stage method, was 8.1/1,000 individuals (95%CI: 7.5--8.7).

Within the population sample of 3,889 (611 not found due to permanent out-migration from the study area) the crude prevalence was 6.7/1,000 individuals (95%CI: 4.1--9.3), while the adjusted prevalence (adjusting for attrition and sensitivity (76.7%) of the two-stage method against the gold standard ([@bib0135])) was 9.8/1,000 individuals (95% CI: 6.9--13.4).

The adjusted prevalence of ACE by village ranged from 1.8--15.0/1,000 individuals ([Table 2](#tbl0010){ref-type="table"}) and this variation was statistically significant (*p* = 0.05), although the response rate for Stage 1 and Stage 2 did not vary between villages.

Age of onset of epilepsy {#sec0070}
------------------------

239 individuals reported age of onset of their seizures. The distribution of age of onset was left-skewed with 7.1% (*n* = 17) experiencing seizures within the first year of life ([Fig. 3](#fig0015){ref-type="fig"}) and 30.8% (*n* = 74) before 5 years. The median age at onset was 12 years interquartile range was 0--23 years.

Factors associated with epilepsy {#sec0075}
--------------------------------

Of the 311 cases of ACE identified (245 from the three-stage survey, 10 additional cases from the population sample, and 56 cases referred from other sources), 292 cases (94%) were matched to 260 controls. The matching was not 1:1 due to a high proportion of refusals in the controls.

Univariate analysis {#sec0080}
-------------------

Within the univariate analysis, male sex, family history of seizures, a sibling with seizures, problems after delivery, loss of consciousness during head injury and history of snoring at least three nights per week were associated with ACE. ACE was not associated with exposure to any of the parasites tested and none of the cases had antibodies to *T. solium*.

For individuals \>18 years, neither alcohol consumption nor length of alcohol consumption was associated with ACE.

For individuals \<18 years, having a mother with some history of formal education reduced her child\'s risk of ACE (OR = 0.34; 95%CI 0.12--0.94), while history of snoring at least three nights per week (OR = 6.51; 95%CI 3.25--13.06) was associated with an increased prevalence of ACE. Neither the mother\'s level of formal education nor mother\'s marital status were significantly associated with ACE.

Multivariate modeling {#sec0085}
---------------------

After controlling for age and sex, a family member with seizures, a sibling with seizures, problems after delivery, and history of snoring at least three nights per week were associated with ACE ([Table 3](#tbl0015){ref-type="table"}).

Additionally, for individuals \<18 years, a mother with formal education (OR = 0.30; 95%CI 0.11--0.84) was found to be protective.

While head injury was not associated with ACE in the multivariate model, males were twice as likely to experience head injury (OR = 2.01; 95%CI 1.06--3.88) when compared with females.

Discussion {#sec0090}
==========

From this community-based research in rural northeast South Africa, we found the prevalence of epilepsy in a rigorous three-stage study to be lower than that reported elsewhere in sub-Saharan Africa (SSA). After adjusting for the sensitivity of the screening tool and attrition in the three stage survey, our findings remain lower than the 12.7/1,000 cases of active epilepsy reported in a meta-analysis of studies in rural areas of LMICs ([@bib0140]) and other SEEDS sites in SSA ([@bib0145]). This could be explained by differences in methodology or risk factors ([@bib0145]). ACE may only constitute 25% of all epilepsies ([@bib0030; @bib0050]). In high-income countries, only half of the epilepsies are convulsive and about half of patients with convulsive epilepsy experienced a seizure within the last year ([@bib0030]). Therefore, the real prevalence of active epilepsy may well be higher than the adjusted, age-standardized prevalence found in this study (8.1/1,000). Furthermore, the increased mortality associated with epilepsy in Africa ([@bib0045]) and the higher rates of spontaneous remission ([@bib0130]) may lower the prevalence of active epilepsy. We suspect the lower unadjusted prevalence figure recorded in the three-stage study may also be the result of social stigma. A recent study from Kenya found that false negative individuals in a similar three-stage study reported higher stigma scores on a validated stigma scale than those positively identified in Stage I ([@bib0135]). While stigma levels are likely to vary depending on social perceptions of epilepsy, further research is needed to define the extent of under-reporting.

Prevalence by sex {#sec0095}
-----------------

Epilepsy studies from SSA report varying levels of prevalence by sex ([@bib0015]). Our data suggest that males are more likely to develop epilepsy than females during the first two decades of life, perhaps due to risk factor patterns discussed below.

Age of onset {#sec0100}
------------

These findings from rural South Africa replicate those found in Tanzania and Ethiopia as well as the other SEEDS sites (Kenya, Tanzania, Uganda and Ghana), which suggest that the highest incidence of epilepsy occurs in the first decade of life ([@bib0175; @bib0185; @bib0145]). We found the onset of epilepsy to be greatest in the first year of life, which is supported by our case-control data in which problems after delivery were associated with ACE. Underlying genetic or congenital abnormalities could possibly be important causes of epilepsy in this community. The second peak of onset during adolescence (10--15 years) may be indicative of environmental, infectious and traumatic risk factors. The increased onset during the fourth decade of life (30--39 years) may reflect the bimodal distribution of epilepsy seen in high-income countries ([@bib0215]). South Africa is experiencing increasing levels of cardiovascular disease ([@bib0110]), which may increase the incidence of epilepsy later in life, although this tends to occur at younger age in populations undergoing epidemiological transition than in high income populations ([@bib0035]). Further research is needed to determine the underlying causes of symptomatic epilepsy in rural South Africa.

Prevalence by village of residence {#sec0105}
----------------------------------

There are a number of possible reasons for the inter-village heterogeneity of the prevalence of ACE across the Agincourt sub-district. While attrition of respondents between stages did not vary significantly by village, it is possible that under-reporting of convulsions in Stage I (suggested by 10 false-negatives in the population sample) contributed to the observed village-level heterogeneity. Differences in response rates and awareness of epilepsy have been highlighted as possible causes of heterogeneity in small areas ([@bib0050]).

Genetic abnormalities, exposure to a particular environmental risk factor, or access to health facilities (in terms of perinatal care) may also contribute to the heterogeneity, as we identified several households with more than one person with epilepsy. Ultimately, however, it is possible that the heterogeneity is due to combination of factors or may reflect the actual distribution of epilepsy in a rural South African setting.

Factors associated with ACE {#sec0110}
---------------------------

The factors associated with ACE were different in Agincourt compared to other SEEDS sites ([@bib0145]).

### Sex {#sec0115}

We found a higher prevalence in males than in females, which replicates other studies from SSA ([@bib0170]). Being male may put an individual at greater risk for known risk factors, such as head injury. Within this study, males with epilepsy were twice as likely to have experienced a head injury than females with epilepsy. Road traffic accidents and assault--both common causes of traumatic brain injury and potential risk factors for epilepsy--were found to be leading causes of death in individuals aged 15--49 years within the Agincourt sub-district ([@bib0195]). Furthermore, it has also been reported that females are more likely to hide their epilepsy ([@bib0170]), which may contribute to the higher prevalence observed in males.

### Family history of seizures {#sec0120}

A family history of seizures was shown to be a significant risk factor for developing convulsive epilepsy in this study, as in other studies from SSA ([@bib0050; @bib0105; @bib0155]). Small numbers in our study limited exploration of relationships between family members experiencing seizures; however, this study did find that having a sibling with seizures is a significant risk factor for epilepsy. Further research could explore these relationships and the underlying etiology to assess the balance between genetic, social and environmental exposures. The large and closely related family samples in much of rural SSA could support expanded research into genetic risk factors for ACE ([@bib0055]).

### Adverse perinatal events {#sec0125}

Problems after delivery were found to be a risk factor for developing epilepsy, while problems during delivery do not appear to be a risk factor. Studies from Tanzania and Burundi found the risk of developing ACE to be 4.5 and 1.9 times greater, respectively, after perinatal complications ([@bib0105; @bib0155]). In the current study, at least 60% of births occurred at clinics or hospitals. In this regard, rural South Africa may differ from the rest of SSA where most children are born at home without professional support ([@bib0040]).

### Snoring {#sec0130}

Snoring was included to detect sleep disturbance in people with epilepsy, as documented elsewhere ([@bib0060]). We found that snoring was significantly associated with ACE, though snoring was not associated with body mass index, age or sex. Snoring is a symptom in obstructive sleep apnea (OSA) ([@bib0005]) and a number of studies have found a high prevalence of sleep disorders, including OSA, in people with epilepsy ([@bib0010; @bib0095; @bib0100; @bib0080]). While snoring was associated with ACE in this study, we cannot extrapolate any temporal relationship or etiological association between snoring and seizures. Furthermore, snoring may be a risk factors or a consequence of a co-morbid condition, such as sleep apnea. Additional research is warranted to better understand this unusual finding.

### Mother\'s experience with formal education {#sec0135}

In individuals \<18 years of age, having a mother who attended some formal education was found to be a protective factor, which differs from earlier research in LMICs ([@bib0070; @bib0115]). Education is often linked with higher socio-economic status, which in turn can be linked with better access to healthcare. Further research to establish the temporality and causal pathway of a mother\'s education as a protective factor for her child developing ACE is warranted.

Infections known to be associated with ACE {#sec0140}
------------------------------------------

Toxocara, toxoplasmosis, HIV and malaria were not significantly associated with ACE in this study, which differs from other SEEDS sites ([@bib0145]). None of the patients with ACE had evidence of exposure to neurocysticercosis, an established risk factor for epilepsy in other parts of Africa. These results differ markedly from the Eastern Cape province of South Africa, where an estimated 34,662 cases (95% CI: 17,167--54,068) of epilepsy related to neurocysticercosis occurred in 2004 ([@bib0020]). This difference is likely the result of very little free-range pig farming within the Agincourt sub-district and regionally, coupled with some local religions forbidding consumption of pork.

### Human immunodeficiency virus (HIV) {#sec0145}

Surprisingly, we did not find HIV infection to be a risk factor for ACE, even though the prevalence of HIV infection in this area is high (18% of cases and 23% of controls in this study) ([@bib0065]). While HIV was not shown to be a risk factor for ACE, studies elsewhere report new-onset seizures to be associated with HIV infection and subsequent opportunistic infections ([@bib0180]). HIV was furthermore not associated with adult onset epilepsy nor was toxoplasmosis associated with HIV in this study. Due to the cross-sectional design of this study, individuals at risk for epilepsy, because of an opportunistic infection due to HIV, may be missed due to early mortality. More research on interactions between HIV and epilepsy is indicated, particularly in the absence of opportunistic cerebral infections.

Conclusion {#sec0150}
==========

This study, the largest population-based epilepsy study in rural South Africa to-date, found convulsive epilepsy to be less frequent in this area than in other parts of SSA, with significant heterogeneity between villages. The lower prevalence levels of epilepsy found in this study could be due to the definition of epilepsy used in this study, increased access to professional support during birth leading to reduced adverse perinatal events or lack of parasites. More than half of all patients had the onset of seizures within the first two decades of life and risk factors include a family history of seizures, problems during delivery, and a history of snoring. HIV was not found to be a risk factor for developing ACE. Given the substantial burden of epilepsy, further research on the burden, including morbidity and mortality, as well as treatment options for and economic burden of epilepsy in rural SSA is warranted.
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###### 

Crude and adjusted prevalence of ACE by age and sex, Agincourt sub-district, South Africa 2008.

  Age band         Cases of ACE   Crude prevalence   95% Confidence interval   Adjusted prevalence   95% Confidence interval
  ---------------- -------------- ------------------ ------------------------- --------------------- -------------------------
  0 to 5 years     10             0.87               0.33--1.41                2.18                  0.88--3.48
  6 to 12 years    29             2.23               1.42--3.03                4.79                  3.09--6.52
  13 to 18 years   34             2.76               1.83--3.68                6.38                  4.32--8.42
  19 to 28 years   47             2.65               1.89--3.40                6.23                  4.47--7.98
  29 to 49 years   87             4.70               3.71--5.69                10.95                 8.74--13.13
  50+ years        38             3.94               2.68--5.19                9.55                  6.69--12.41
  Male             129            3.24               2.68--3.80                7.43                  5.53--7.82
  Female           116            2.69               2.20--3.18                6.50                  4.53--6.54

###### 

Adjusted prevalence of active convulsive epilepsy by village of residence, Agincourt sub-district, 2008.

  Village[a](#tblfn0005){ref-type="table-fn"}   Cases of ACE   Adjusted prevalence   95% Confidence interval
  --------------------------------------------- -------------- --------------------- -------------------------
  A                                             7              7.17                  5.36--9.40
  B                                             3              2.77                  1.26--5.25
  C                                             20             6.21                  4.30--8.67
  D                                             22             10.92                 7.78--14.90
  E                                             6              6.31                  3.74--9.96
  F                                             11             5.46                  3.34--8.42
  G                                             9              7.24                  4.22--11.57
  H                                             13             4.67                  2.99--6.84
  I                                             1              6.84                  4.68--9.65
  J                                             2              5.1                   3.27--7.58
  K                                             11             7.39                  5.49--9.73
  L                                             3              3.02                  1.12--6.21
  M                                             6              3.02                  1.21--6.21
  N                                             1              6.77                  4.30--10.14
  O                                             6              11.41                 7.07--17.38
  P                                             10             8.45                  5.53--12.35
  Q                                             7              10.04                 7.25--13.55
  R                                             17             14.98                 10.06--21.45
  S                                             18             6.64                  2.67--13.62
  T                                             11             3.03                  0.06--8.83
  U                                             16             9.91                  5.67--16.04
  V                                             10             7.2                   5.24--9.66
  W                                             4              7.07                  4.05--11.46
  X                                             10             9.96                  6.17--15.18
  Y                                             21             1.77                  0.21--6.28
  Overall                                       245            7.01                  6.23--7.78

Villages have been anonymized due to small village size and confidentiality of individuals with ACE.

###### 

Multivariate analysis of possible risk factors associated with active convulsive epilepsy, Agincourt sub-district, 2008.

  Variable of interest                              Controls (*n* = 260)   Cases (*n* = 292)   Odds ratio (95% CI)[a](#tblfn0010){ref-type="table-fn"}   *p*-value
  ------------------------------------------------- ---------------------- ------------------- --------------------------------------------------------- -----------
  Sex                                                                                                                                                    
   Female                                           176 (67)               142 (49)            1                                                         
   Male                                             85 (33)                150 (51)            2.27 (1.60--3.23)                                         \<0.001
  Family history of non-febrile seizures                                                                                                                 
   Someone in family with seizures                  11 (4)                 41 (14)             4.01 (1.99--8.09)                                         \<0.001
   Someone in family with past history of seizure   0 (0)                  12 (4)              [b](#tblfn0015){ref-type="table-fn"}                      \<0.001
   Mother with Seizures                             0 (0)                  3 (1)               [b](#tblfn0015){ref-type="table-fn"}                      0.146
   Father with seizures                             1 (0)                  2 (1)               1.87 (0.16--21.7)                                         0.615
   Sibling with seizure                             2 (1)                  14 (5)              7.05 (1.57--31.68)                                        0.011
  Location of birth                                                                                                                                      
   Hospital                                         9 (5)                  17 (6)              1                                                         
   Clinic                                           109 (62)               144 (54)            0.68 (0.29--1.60)                                         0.379
   Home                                             57 (32)                97 (36)             0.66 (0.26--1.66)                                         0.379
   Unknown                                          2 (1)                  8 (3)               1.58 (0.267--9.38)                                        0.612
  Adverse perinatal events                                                                                                                               
   Normal delivery                                  163 (96)               246 (93)            1                                                         
   Abnormal delivery                                7 (4)                  19 (7)              2.05 (0.81--5.15)                                         0.128
   No problems after delivery                       174 (99)               249 (94)            1                                                         
   Problems after delivery                          2 (1)                  14 (5)              5.93 (1.18--24.58)                                        0.030
   History of febrile seizures                      0 (0)                  3 (1)               [b](#tblfn0015){ref-type="table-fn"}                      0.101
  History of head trauma                                                                                                                                 
   No history of head injury                        245 (94)               260 (89)            1                                                         
   History of head injury                           16 (6)                 31 (11)             1.57 (0.82--2.99)                                         0.170
   Loss of consciousness with the head injury       3 (19)                 20 (65)             2.69 (0.68--10.61)                                        0.157
  Sociodemographic and clinical characteristics                                                                                                          
   Abnormal skull shape                             0 (0)                  23 (8)              [b](#tblfn0015){ref-type="table-fn"}                      \<0.001
   History of eating cassava                        154 (59)               190 (66)            1.31 (0.92--1.88)                                         0.137
   History of eating pork                           69 (26)                59 (20)             0.70 (0.47--1.04)                                         0.078
   History of eating soil                           19 (7)                 18 (6)              1.05 (0.53--2.08)                                         0.878
   History of dogs in dwelling                      52 (20)                68 (23)             1.17 (0.77--1.77)                                         0.457
   History of cats in dwelling                      22 (8)                 16 (6)              0.64 (0.33--1.27)                                         0.202
   History of snoring (at least 3x/week)            51 (20)                187 (64)            6.51 (4.45--9.53)                                         \<0.001
  Serological variables                                                                                                                                  
   Positive for malarial antibodies                 71 (33)                78 (39)             1.16 (0.76--1.78)                                         0.485
   Positive for HIV antibodies                      49 (23)                36 (18)             0.73 (0.44--1.21)                                         0.226
   Toxocara                                         77 (36)                73 (37)             1.17 (0.78--1.79)                                         0.444
   Toxoplasmosis                                    22 (10)                27 (14)             1.20 (0.64--2.25)                                         0.580
   *n* (%)                                                                                                                                               

Odd Ratios adjusted for age and sex.

Indicates that an Odds ratio could not be calculated due to zero exposure in the control population.
